tetano
Editor, Senior Moderator
Clin Respir J
. 2024 Jan;18(1):e13719.
doi: 10.1111/crj.13719. Epub 2023 Dec 20. Acquired tracheomalacia due to SARS-CoV-2 pneumonia
David Espejo[SUP] 1 [/SUP], Marta Zapata[SUP] 1 [/SUP], Saliha Omari[SUP] 1 [/SUP], Xavier Muñoz[SUP] 1 2 3 [/SUP], Maria-Jesús Cruz[SUP] 1 2 [/SUP]; Se‐COVID‐19 team
Collaborators, Affiliations
Introduction: Several studies mentioned parenchymal findings after SARS-CoV-2 pneumonia, but few studies have mentioned alterations in the airways. The aim of this study was to estimate the prevalence of tracheomalacia and to analyse the clinical characteristics in a cohort of patients with SARS-CoV-2.
Methods: The study population consisted of all patients with SARS-CoV-2 admitted a hospital serving a population of 500 000 inhabitants. Patients were visited between 2 and 6 months after hospital discharge. In this visit, all patients were subjected to an exhaustive clinical questionnaire and underwent clinical examination, pulmonary function tests and chest CT.
Results: From February 2020 to August 2021, 1920 patients were included in the cohort and tracheomalacia was observed in 15 (0.8%) on expiratory HRCT imaging. All patients with tracheomalacia also presented ground glass opacities in the CT scan and 12 patients had airway sequelae.
Conclusions: Tracheomalacia is an exceptional sequela of SARS-CoV-2 survivors.
Keywords: COVID‐19; infection; inflammation.
. 2024 Jan;18(1):e13719.
doi: 10.1111/crj.13719. Epub 2023 Dec 20. Acquired tracheomalacia due to SARS-CoV-2 pneumonia
David Espejo[SUP] 1 [/SUP], Marta Zapata[SUP] 1 [/SUP], Saliha Omari[SUP] 1 [/SUP], Xavier Muñoz[SUP] 1 2 3 [/SUP], Maria-Jesús Cruz[SUP] 1 2 [/SUP]; Se‐COVID‐19 team
Collaborators, Affiliations
- PMID: 38666787
- PMCID: PMC10788234
- DOI: 10.1111/crj.13719
Introduction: Several studies mentioned parenchymal findings after SARS-CoV-2 pneumonia, but few studies have mentioned alterations in the airways. The aim of this study was to estimate the prevalence of tracheomalacia and to analyse the clinical characteristics in a cohort of patients with SARS-CoV-2.
Methods: The study population consisted of all patients with SARS-CoV-2 admitted a hospital serving a population of 500 000 inhabitants. Patients were visited between 2 and 6 months after hospital discharge. In this visit, all patients were subjected to an exhaustive clinical questionnaire and underwent clinical examination, pulmonary function tests and chest CT.
Results: From February 2020 to August 2021, 1920 patients were included in the cohort and tracheomalacia was observed in 15 (0.8%) on expiratory HRCT imaging. All patients with tracheomalacia also presented ground glass opacities in the CT scan and 12 patients had airway sequelae.
Conclusions: Tracheomalacia is an exceptional sequela of SARS-CoV-2 survivors.
Keywords: COVID‐19; infection; inflammation.